Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Gross Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Gross Margin over the past 16 years, most recently at 38.37% for Q2 2025.

  • Quarterly results put Gross Margin at 38.37% for Q2 2025, down 722.0% from a year ago — trailing twelve months through May 2025 was 31.27% (down 136.0% YoY), and the annual figure for FY2025 was 31.27%, down 136.0%.
  • Gross Margin for Q2 2025 was 38.37% at Lifecore Biomedical, Inc. \De\, up from 28.01% in the prior quarter.
  • Over the last five years, Gross Margin for LFCR hit a ceiling of 45.59% in Q2 2024 and a floor of 11.12% in Q3 2023.
  • Median Gross Margin over the past 5 years was 32.74% (2023), compared with a mean of 31.39%.
  • Biggest five-year swings in Gross Margin: soared 2620bps in 2021 and later crashed -1878bps in 2022.
  • Lifecore Biomedical, Inc. \De\'s Gross Margin stood at 44.76% in 2021, then crashed by -42bps to 25.97% in 2022, then grew by 27bps to 33.02% in 2023, then rose by 3bps to 34.04% in 2024, then increased by 13bps to 38.37% in 2025.
  • The last three reported values for Gross Margin were 38.37% (Q2 2025), 28.01% (Q1 2025), and 34.04% (Q4 2024) per Business Quant data.